An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma

ID Number 16-0191

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to see if subcutaneous (SC) daratumumab is safe, well tolerated and to find out how long SC daratumumab remains in and acts on the body.  The purpose of this study is to also find out how your body responds to daratumumab after a SC or IV infusion and how useful daratumumab is in treating multiple myeloma.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: Yes